Literature DB >> 15989899

Update on the drug treatment of hypertension in patients with cardiovascular disease.

William B White1.   

Abstract

The management of the high-risk patient with hypertension has become more challenging in recent years. Drug therapy should be initiated earlier and at lower blood pressure levels in patients with coexisting cardiovascular or kidney diseases. The blood pressure goals of drug therapy are substantially lower when patients have concomitant heart or kidney disease or diabetes mellitus. Numerous clinical trials in tens of thousands of hypertensive patients with increased cardiovascular risk have demonstrated that the calcium antagonists are as effective and safe as diuretics, beta-adrenergic blockers, and renin-angiotensin blocking agents to prevent heart attack and stroke but not heart failure. Several recent studies also demonstrate that angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are effective in preventing stroke, progressive renal insufficiency, and heart failure in higher risk patients with hypertension. To achieve the aggressive blood pressure goals in patients with cardiovascular disease, thoughtful combinations of additive or synergistic agents improve efficacy and tolerability and have become an integral part of the modern management of hypertensive patients with coexisting cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15989899     DOI: 10.1016/j.amjmed.2005.01.071

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Outpatient Hypertension Control and Prescribing Habits for Hypertension in Taiwan.

Authors:  Chung-Sheng Lin; Yung-Hua Chu; Yi-Jen Hung; Du-Yi Lee; Cheng-Yun Chen
Journal:  Acta Cardiol Sin       Date:  2013-11       Impact factor: 2.672

Review 2.  Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy.

Authors:  Peter P Toth
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-10-05       Impact factor: 3.738

3.  Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.

Authors:  James R Sowers; Joel M Neutel; Elijah Saunders; George L Bakris; William C Cushman; Keith C Ferdinand; Elizabeth O Ofili; Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-07       Impact factor: 3.738

Review 4.  Pharmacologic agents in the management of hypertension--nisoldipine coat-core.

Authors:  William B White
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-04       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.